In the Cambodian CAMELIA trial, where the median CD4 count at drug-susceptible TB treatment start was less than 50 cells/mm3, there was a significant impact on mortality when ART was initiated two weeks after TB treatment compared to eight weeks [15]. Here, CD4 is linked to tuberculosis.